Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: A matched case control study

Geert A. Simkens; Thijs R. Van Oudheusden; Hidde J. Braam; Marinus J. Wiezer; Simon W. Nienhuijs; Harm J. Rutten; Bert Van Ramshorst; Ignace H. de Hingh

doi:10.1002/jso.24169

Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: A matched case control study

Geert A. Simkens
, Thijs R. Van Oudheusden
, Hidde J. Braam
, Marinus J. Wiezer
, Simon W. Nienhuijs
, Harm J. Rutten
, Bert Van Ramshorst
, Ignace H. de Hingh

Research output: Contribution to journal › Article › Academic › peer-review

20 Citations (Scopus)

Abstract

BACKGROUND & OBJECTIVES: The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case-control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients.

METHODS: Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case-matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short- and long-term outcomes were compared between both groups.

RESULTS: From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1%) had rectal PM. Fifty-eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6% and 34.5% in the rectal and colon group, respectively (P = 0.516). Median disease-free survival was 13.5 months in the rectal group and 13.6 months in the colon group (P = 0.621). Two- and five-year overall survival rates were 54%/32% in rectal cancer patients, and 61%/24% in colon cancer patients (P = 0.987).

CONCLUSIONS: Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra-indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548-553. © 2016 Wiley Periodicals, Inc.

Original language	English
Pages (from-to)	548-553
Number of pages	6
Journal	Journal of Surgical Oncology
Volume	113
Issue number	5
DOIs	https://doi.org/10.1002/jso.24169
Publication status	Published - 1 Apr 2016
Externally published	Yes

Keywords

Aged
Case-Control Studies
Chemotherapy, Cancer, Regional Perfusion
Colonic Neoplasms/mortality
Combined Modality Therapy
Cytoreduction Surgical Procedures
Disease-Free Survival
Female
Humans
Hyperthermia, Induced
Male
Middle Aged
Peritoneal Neoplasms/mortality
Rectal Neoplasms/mortality
Survival Rate
Treatment Outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jso.24169

Cite this

Simkens, G. A., Van Oudheusden, T. R., Braam, H. J., Wiezer, M. J., Nienhuijs, S. W., Rutten, H. J., Van Ramshorst, B., & de Hingh, I. H. (2016). Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: A matched case control study. Journal of Surgical Oncology, 113(5), 548-553. https://doi.org/10.1002/jso.24169

@article{4a93cc762c6b4609811cefa5b89e1613,

title = "Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: A matched case control study",

abstract = "BACKGROUND \& OBJECTIVES: The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case-control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients.METHODS: Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case-matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short- and long-term outcomes were compared between both groups.RESULTS: From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1\%) had rectal PM. Fifty-eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6\% and 34.5\% in the rectal and colon group, respectively (P = 0.516). Median disease-free survival was 13.5 months in the rectal group and 13.6 months in the colon group (P = 0.621). Two- and five-year overall survival rates were 54\%/32\% in rectal cancer patients, and 61\%/24\% in colon cancer patients (P = 0.987).CONCLUSIONS: Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra-indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548-553. {\textcopyright} 2016 Wiley Periodicals, Inc.",

keywords = "Aged, Case-Control Studies, Chemotherapy, Cancer, Regional Perfusion, Colonic Neoplasms/mortality, Combined Modality Therapy, Cytoreduction Surgical Procedures, Disease-Free Survival, Female, Humans, Hyperthermia, Induced, Male, Middle Aged, Peritoneal Neoplasms/mortality, Rectal Neoplasms/mortality, Survival Rate, Treatment Outcome",

author = "Simkens, \{Geert A.\} and \{Van Oudheusden\}, \{Thijs R.\} and Braam, \{Hidde J.\} and Wiezer, \{Marinus J.\} and Nienhuijs, \{Simon W.\} and Rutten, \{Harm J.\} and \{Van Ramshorst\}, Bert and \{de Hingh\}, \{Ignace H.\}",

year = "2016",

month = apr,

day = "1",

doi = "10.1002/jso.24169",

language = "English",

volume = "113",

pages = "548--553",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "5",

}

Simkens, GA, Van Oudheusden, TR, Braam, HJ, Wiezer, MJ, Nienhuijs, SW, Rutten, HJ, Van Ramshorst, B & de Hingh, IH 2016, 'Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: A matched case control study', Journal of Surgical Oncology, vol. 113, no. 5, pp. 548-553. https://doi.org/10.1002/jso.24169

Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: A matched case control study. / Simkens, Geert A.; Van Oudheusden, Thijs R.; Braam, Hidde J. et al.
In: Journal of Surgical Oncology, Vol. 113, No. 5, 01.04.2016, p. 548-553.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients

T2 - A matched case control study

AU - Simkens, Geert A.

AU - Van Oudheusden, Thijs R.

AU - Braam, Hidde J.

AU - Wiezer, Marinus J.

AU - Nienhuijs, Simon W.

AU - Rutten, Harm J.

AU - Van Ramshorst, Bert

AU - de Hingh, Ignace H.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - BACKGROUND & OBJECTIVES: The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case-control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients.METHODS: Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case-matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short- and long-term outcomes were compared between both groups.RESULTS: From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1%) had rectal PM. Fifty-eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6% and 34.5% in the rectal and colon group, respectively (P = 0.516). Median disease-free survival was 13.5 months in the rectal group and 13.6 months in the colon group (P = 0.621). Two- and five-year overall survival rates were 54%/32% in rectal cancer patients, and 61%/24% in colon cancer patients (P = 0.987).CONCLUSIONS: Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra-indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548-553. © 2016 Wiley Periodicals, Inc.

AB - BACKGROUND & OBJECTIVES: The effect of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with rectal peritoneal metastases (PM) is unclear. This case-control study aims to assess the results of cytoreduction and HIPEC in patients with rectal PM compared to colon PM patients.METHODS: Colorectal PM patients treated with complete macroscopic cytoreduction and HIPEC were included. Two colon cancer patients were case-matched for each rectal cancer patient, based on prognostic factors (T stage, N stage, histology type, and extent of PM). Short- and long-term outcomes were compared between both groups.RESULTS: From 317 patients treated with complete macroscopic cytoreduction and HIPEC, 29 patients (9.1%) had rectal PM. Fifty-eight colon cases were selected as control patients. Baseline characteristics were similar between groups. Major morbidity was 27.6% and 34.5% in the rectal and colon group, respectively (P = 0.516). Median disease-free survival was 13.5 months in the rectal group and 13.6 months in the colon group (P = 0.621). Two- and five-year overall survival rates were 54%/32% in rectal cancer patients, and 61%/24% in colon cancer patients (P = 0.987).CONCLUSIONS: Cytoreduction and HIPEC in selected patients with rectal PM is feasible and provides similar outcomes as in colon cancer patients. Rectal PM should not be regarded a contra-indication for cytoreduction and HIPEC in selected patients. J. Surg. Oncol. 2016;113:548-553. © 2016 Wiley Periodicals, Inc.

KW - Aged

KW - Case-Control Studies

KW - Chemotherapy, Cancer, Regional Perfusion

KW - Colonic Neoplasms/mortality

KW - Combined Modality Therapy

KW - Cytoreduction Surgical Procedures

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Hyperthermia, Induced

KW - Male

KW - Middle Aged

KW - Peritoneal Neoplasms/mortality

KW - Rectal Neoplasms/mortality

KW - Survival Rate

KW - Treatment Outcome

UR - https://www.scopus.com/pages/publications/84954543498

U2 - 10.1002/jso.24169

DO - 10.1002/jso.24169

M3 - Article

C2 - 27110701

SN - 0022-4790

VL - 113

SP - 548

EP - 553

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 5

ER -

Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: A matched case control study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this